Lifecore Biomedical Overview
Valuation check: LFCR's ROE is -167.5%, below the Materials sector average of 19.67%.
Get informed when a big investor buys or sells
+ Follow-167.50%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for LFCR is -167.5%. That is below the Materials sector average of 19.67%. Investors often review this figure alongside Lifecore Biomedical's historical trend and sector peers before judging valuation or financial health.
Against Materials companies, LFCR currently prints -167.5% for ROE, while the sector average sits near 19.67%. That is roughly 951.4% below the sector mean. Large gaps often invite a closer look at Lifecore Biomedical's growth, margins, and balance sheet.
Return on Equity shows how effectively Lifecore Biomedical converts resources into returns. At -167.5%, LFCR may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting LFCR's ROE (-167.5%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Lifecore Biomedical's ROE against similar Materials names. You can also browse sector and industry screens on Stockcircle for a broader set of Materials companies and their key multiples and fundamentals.
